Clinical Trials Logo

Clinical Trial Details — Status: Not yet recruiting

Administrative data

NCT number NCT06117488
Other study ID # chronic portal vein thrombosis
Secondary ID
Status Not yet recruiting
Phase
First received
Last updated
Start date November 1, 2023
Est. completion date December 1, 2025

Study information

Verified date November 2023
Source Assiut University
Contact Asmaa Aly Fathy, resident doctor
Phone 01096925454
Email asmaaali199732@gmail.com
Is FDA regulated No
Health authority
Study type Observational

Clinical Trial Summary

The aim of study is to evaluate different etiological and risk factors that lead to chronic portal vein thrombosis and to delineate a management plan for chronic portal vein thrombosis in children.


Description:

Chronic Portal vein thrombosis (PVT) is defined as thrombosis that develops in the trunk of the portal vein, including its right and/or left intrahepatic branches of more than 5 weeks duration. This thrombus may extend to the splenic or superior mesenteric veins. The causes of chronic PVT in children are not entirely known, but several factors that predispose to this pathology are described. These are classified into three categories: local factors that can cause injury to the portal vein (abdominal infections, abdominal surgery, umbilical catheter), general factors (procoagulant status), and, less often, vascular malformation. The most common cause is umbilical vein catheterization (UVC). Among the general factors that predispose to venous thrombosis are thrombophilia, sepsis, and dehydration. Deficiency or qualitative abnormalities of anti-coagulation factors (antithrombin III, protein C, protein S, and activated protein C resistance) often predispose to thrombotic events, including PVT. Thrombophilia is incriminated in 35% of cases of PVT in children. For this reason, children with PVT, and especially those that associate other risk factors (UVC), should be screened for inherited prothrombotic disorders: prothrombin 20210 mutation (PTHR), factor V Leiden (FVL), methylenetetrahydrofolate reductase (MTHFR) genes deficiency, or metabolic defects like hyper homocysteinemia. Congenital abnormalities (portal vein stenosis, atresia, or agenesis) are rarely involved in PVT. Furthermore, early PVT after liver transplantation with cadaveric graft was described in adults. Even less often in children, PVT after splenectomy for hematologic diseases was also described. An association between more than one factor is frequently observed, which further increases the risk of thrombosis. In almost 50% of cases, the etiology of PVT remains unknown. PVT patients initially present with upper gastrointestinal bleeding (UGIB) or splenomegaly on routine clinical examination in asymptomatic individuals. The initial presence of hematemesis is usually dramatic in a previously healthy child, with past history of morbidity, often without remarkable intercurrent events. Melena may also be observed, but it is less common than hematemesis. The child can be lethargic, with signs of orthostatic hypotension. The clinical examination revealing splenomegaly in a child with UGIB indicates esophageal varices as the most probable site for the bleeding. Less frequently, the diagnosis can be based on the investigation of a child with abdominal pain or with complications related to hypersplenism. The physical examination may reveal splenomegaly; hepatomegaly is not common in children with PVT without underlying liver disease, as well as stigmata of chronic liver disease. PVT should be suspected in all children with splenomegaly, without hepatomegaly and hematemesis, with normal liver function test results. Liver biopsy is normal in children without associated cirrhosis. Abdominal Doppler ultrasonography is the most widely used diagnostic exam in pediatric patients, with a high sensitivity and specificity, even though it is an operator-dependent diagnostic method. Chronicity of PVT is defined by Doppler ultrasonography by means of visualization of the formation of new vessels around the thrombus (cavernoma). Some diagnostic exams should not be routinely used in pediatric patients due to their risk: splenoportography and arterial portography, nuclear magnetic resonance (angiography), computed tomography (portogram). All patients must be submitted to upper gastrointestinal endoscopy to check for the presence of esophagogastric varices, which will allow for a better planned therapeutic approach. Laboratory exams show normal liver function in most patients, except in those who have a prolonged decrease in portal circulation, or portal biliopathy. The treatment of portal venous obstruction depends upon the patient's age, the site and nature of the obstruction and the clinical features. Endoscopic variceal ligation (EVL) is the primary choice for the management of variceal bleeding in children. This treatment may be technically difficult in young and small children; sclerotherapy is then recommended as an alternative approach in such cases. Beta adrenergic blockade may play a role in secondary prophylaxis as they reduce the risk of rebleeding and improve survival after variceal bleed. Decompressive shunt surgery should be considered in cases with failed endotherapy. It is also indicated for correcting symptomatic portal hypertensive biliopathy, symptomatic hypersplenism and 'on demand' one-time treatment. Oesophageal transection with or without splenectomy is less useful to control bleeding because of a high risk of late rebleeding and reappearance of varices, but can be resorted to as a nonshunt option in patients with portosystemic encephalopathy, hepatopulmonary syndrome or portopulmonary syndrome. Portal vein thrombosis was considered a major obstacle to liver transplantation which led to increased surgical complexity and perioperative morbidity and mortality.


Recruitment information / eligibility

Status Not yet recruiting
Enrollment 30
Est. completion date December 1, 2025
Est. primary completion date December 1, 2024
Accepts healthy volunteers
Gender All
Age group 3 Months to 18 Years
Eligibility Inclusion Criteria: - Children and adolescents with Chronic Portal vein thrombosis admitted to Pediatric Gastroenterology, Hepatology and Endoscopy units at Assiut university children hospital (AUCH) in the previous year 2022 from 1/1/2022 to 31/12/2022. Those with chronic portal vein thrombosis aged from 3 months to 18 years' old. Exclusion Criteria: - Patients aged less than 3 months and more than 18 years' old. Those with acute portal vein thrombosis. Children with portal hypertension in absence of chronic portal vein thrombosis.

Study Design


Related Conditions & MeSH terms


Intervention

Device:
endoscopy
gastro duodenal endoscoe

Locations

Country Name City State
n/a

Sponsors (1)

Lead Sponsor Collaborator
Assiut University

Outcome

Type Measure Description Time frame Safety issue
Primary Risk Factors and Management Outcome of Chronic Portal Vein Thrombosis in Children -Describe demographic and clinical data of children and adolescents with (PVT) admitted to Pediatric Gastroenterology, Hepatology and Endoscopy units at Assiut university children hospital (AUCH) in the previous year 2022. Assess the outcome of (PVT) in children and adolescents admitted to (AUCH).
Describe the distribution of etiologies of (PVT) in children and adolescents at Assiut University Children's Hospital.
-Clinical examination which include:
Vital signs: heart rate, blood pressure, respiratory rate, and temperature.
General examination: pallor, jaundice and cyanosis.
Anthropometric measurements: weight (kg), height (m) and BMI.
Cardiac, chest and neurological examination.
Local abdominal examination for: abdominal distention, hepatomegaly, splenomegaly, ascites and dilated abdominal wall veins.
baseline
See also
  Status Clinical Trial Phase
Not yet recruiting NCT03631147 - The Effect of Rifaximin on Portal Vein Thrombosis N/A
Completed NCT02250391 - Placebo-controlled Study of NPB-06 in Patients With Portal Vein Thrombosis Phase 3
Recruiting NCT05625893 - Proton Beam Radiotherapy Followed by Tecentriq and Avastin for Primary Liver Cancer With Vp2-4 Portal Vein Invasion Phase 2
Completed NCT05012501 - Analysis of Neutrophil Extracellular Traps in Hypercoagulability and Portal Vein Thrombosis in Liver Cirrhosis Patients
Terminated NCT00769873 - Anticoagulation Post Laparoscopic Splenectomy Phase 2
Recruiting NCT05123326 - Global Coagulation Assessment in Portal Vein Thrombosis and Budd-Chiari Syndrome
Completed NCT01095185 - Efficacy of Statin Association With Standard Treatment in Prevention of Recurrent Hemorrhage in Patient With Cirrhosis and Variceal Bleeding Phase 3
Completed NCT02585713 - Apixaban or Dalteparin in Reducing Blood Clots in Patients With Cancer Related Venous Thromboembolism Phase 3
Completed NCT01326949 - Transjugular Intrahepatic Portosystemic Shunt (TIPS) for Prevention of Variceal Rebleeding in Cirrhotic Patients With Portal Vein Thrombosis N/A
Not yet recruiting NCT05339581 - IMRT Plus PD-1 Blockade and Lenvatinib for HCC With PVTT (Vp3) Before Liver Transplantation N/A
Recruiting NCT03902678 - Role of EUS Guided FNA of Portal Vein Thrombus in the Diagnosis and Staging of Hepatocellular Carcinoma N/A
Not yet recruiting NCT06319131 - Nadroparin Versus TIPS in Cirrhotic Patients With Refractory Asymptomatic PVT N/A
Recruiting NCT03193502 - Efficacy and Safety of Rivaroxaban in the Management of Acute Non-neoplastic PVT Compensated Cirrhosis Phase 3
Completed NCT03201367 - Efficacy and Safety of Rivaroxaban in Acute Non-neoplastic Portal Vein Thrombosis in HCV N/A
Completed NCT03477149 - EASYX-1 : A Multicenter Study on Safety and Efficacy of Easyx Liquid Embolization Agent Used in Five Separate Indications N/A
Recruiting NCT02398357 - The Effect of Anticoagulation After Endoscopic Therapy in Cirrhotic Patients With Portal Vein Thrombosis Phase 4
Completed NCT01556282 - TheraSpheres Treatment for Unresectable Hepatocarcinoma and Portal Vein Thrombosis N/A
Withdrawn NCT01631877 - Efficacy and Safety of Acenocoumarol for Treatment of Nontumor Portal Vein Thrombosis in Cirrhosis of Liver N/A
Recruiting NCT04433481 - Efficacy and Safety of Dabigatran in Patients With Cirrhosis and Portal Vein Thrombosis N/A
Not yet recruiting NCT05872841 - H101 Combined With TACE for Primary Hepatocellular Carcinoma With Portal Vein Thrombosis Phase 2